Doximity's model demonstrates a flywheel that every clinical AI company should study — not to copy, but to understand the strategic logic that makes clinical platforms increasingly difficult to compete with once they achieve sufficient scale, workflow breadth, and data density.
The flywheel: clinician network → workflow tools → AI usage → engagement data → insight products → partnerships → partnership revenue → better products → more clinicians → more workflow → more data → more insight. Each layer reinforces the others. The flywheel accelerates with scale. And the competitive moat deepens with every revolution.
Doximity's Flywheel in Numbers
The Q4 FY2026 metrics demonstrate the flywheel operating at scale. Over 800,000 active prescribers using workflow tools — a 30% year-on-year increase and a new engagement record. Nearly half of those prescribers using clinical AI tools — with prompts per user nearly doubling from January to April, suggesting deepening usage per session, not just more users. Full-year revenue $644.9 million, up 13%. Record quarterly free cash flow of $107 million. 140 health systems purchasing the Clinical AI Suite. Aledade and Photon partnerships extending the platform into value-based care and e-prescribing.
Each metric feeds the next in the flywheel logic. More clinician engagement generates more behavioural data (the raw material). More data enables better insight products — DocInsight (the commercial intelligence layer). Better insight products attract life-sciences partnerships (the B2B revenue stream). Partnership revenue funds product development (the reinvestment cycle). Better products attract more clinicians (the growth loop). More clinicians generate more data. The flywheel accelerates.
The acquisitions strengthen specific layers. Pathway Medical ($63 million, 3,200+ drug monographs) deepened the clinical content layer — giving clinicians more reasons to use the platform for drug-information queries. PeerCheck (10,000+ physician reviewers) added the trust layer — giving clinicians confidence that AI answers have been verified by peers. Prescribe/Photon extended the workflow into prescribing — adding another daily use case that generates engagement data. Each addition made the existing layers more valuable.
From Workflow to Insight
DocInsight is strategically coherent because workflow engagement creates data, and data creates intelligence products. Doximity is not adding a consulting division as an afterthought. It is monetising the behavioural data that its core clinical platform generates through daily use — a natural extension of existing value, not a separate business grafted onto it.
The insight products serve the life-sciences market with intelligence that survey-based research cannot provide: physician engagement analytics across clinical topics, clinical AI adoption patterns by specialty and geography, drug-information access behaviour and prescribing correlations, documentation patterns and administrative burden metrics, PeerCheck content performance and trust indicators, and workflow-adoption trends across practice types and settings. Each informs pharmaceutical strategy, medical education planning, market access, evidence generation, and product positioning.
The iatroX Flywheel
iatroX can build a UK version of this flywheel — with different components, different data, different outputs, and different market dynamics, but the same underlying strategic logic.
Ask iatroX generates clinical queries from UK clinicians → source-grounded answers build clinician trust and daily usage → calculators add point-of-care workflow value for specific clinical decisions → CPD creates professional development documentation aligned with GMC/GPhC revalidation → Q-banks support exam preparation across 15+ exams spanning UK, US, Canadian, Australian, and Italian curricula → daily clinical and educational use creates aggregate query patterns across specialties, care settings, and career stages → anonymised aggregate analysis feeds iatroX Insights → insight products and partnership projects generate B2B revenue from digital-health companies, life-sciences organisations, NHS teams, and academic groups → partnership revenue funds product development and content expansion → better clinical products attract more clinicians and learners → the flywheel accelerates.
Each layer generates data that informs the others. Clinical query patterns inform Q-bank content development (ensuring exam preparation covers what clinicians actually struggle with in practice). Calculator usage patterns inform guideline-friction analysis (identifying which clinical scores and risk assessments generate the most queries). Exam preparation patterns inform clinical practice content development (connecting what trainees learn with what practitioners need). CPD patterns inform educational need assessment (mapping where structured learning would have the most impact).
What Makes the UK Flywheel Different
The UK flywheel operates in a healthcare context that differs from the US in specific ways that affect every layer of the model.
Guideline architecture. UK guidelines (NICE, CKS, SmPC/eMC, MHRA, SIGN) define the clinical knowledge infrastructure. Clinical query patterns in the UK reveal different friction points from the US — because the guidelines themselves are different, the prescribing norms are different, the referral pathways are different, and the clinical workflows are structured around NHS service delivery rather than US payer-driven care.
Regulatory standards. MHRA medical device classification, DTAC assessment, DCB 0129/0160 clinical safety cases, and NHS information governance create a regulatory layer that is more structured than the US equivalent — which creates higher barriers to entry but also stronger defensibility for companies that navigate it well. Regulatory competence is a competitive moat in the UK market.
CPD and appraisal. GMC revalidation and GPhC revalidation create mandatory professional development requirements that generate structured engagement data. UK clinicians must demonstrate ongoing learning — and platforms that support CPD documentation create engagement patterns that do not exist in healthcare systems without mandatory revalidation. This engagement is persistent, recurring, and directly linked to professional survival — making it exceptionally sticky.
UK exam pathways. UKMLA, MRCP, MRCGP AKT, GPhC CRA, SCEs, specialist diplomas, FRCA, MRCPCH, MRCPsych — UK exam preparation creates educational engagement that generates data about what trainees struggle with, which topics are underserved by existing resources, and where exam curricula do not adequately prepare for clinical practice. This data directly informs clinical content development for the practitioner-facing platform.
NHS procurement. The B2B layer of the UK flywheel must navigate NHS procurement — institutional decisions, governance requirements, and value-demonstration expectations that differ fundamentally from US enterprise sales or consumer distribution. Understanding NHS procurement dynamics is not optional; it is the mechanism through which B2B partnerships generate institutional adoption.
Commercial Implications
iatroX Insights should not be an add-on page or an afterthought. It should be the B2B layer of the entire platform — the mechanism through which clinical engagement generates commercial value beyond individual user subscriptions and premium exam access. The UK clinical AI market needs a platform that combines clinical utility (for individual clinicians and learners) with strategic intelligence (for partners and health systems) within an ethical governance framework (for everyone).
Doximity demonstrates what this looks like at US scale with US market dynamics. iatroX is building toward the UK equivalent — different market, different data, different intelligence, different regulatory context, same strategic logic: clinical platforms are becoming intelligence engines, and the flywheel is the model.